CY1121296T1 - Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi - Google Patents
Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-williInfo
- Publication number
- CY1121296T1 CY1121296T1 CY20191100034T CY191100034T CY1121296T1 CY 1121296 T1 CY1121296 T1 CY 1121296T1 CY 20191100034 T CY20191100034 T CY 20191100034T CY 191100034 T CY191100034 T CY 191100034T CY 1121296 T1 CY1121296 T1 CY 1121296T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ghrelin
- greelin
- acylinated
- prader
- fragments
- Prior art date
Links
- 201000010769 Prader-Willi syndrome Diseases 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 abstract 10
- 102000012004 Ghrelin Human genes 0.000 abstract 6
- 101800001586 Ghrelin Proteins 0.000 abstract 6
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576217P | 2011-12-15 | 2011-12-15 | |
| PCT/IB2012/002867 WO2013088241A1 (en) | 2011-12-15 | 2012-12-14 | Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121296T1 true CY1121296T1 (el) | 2020-05-29 |
Family
ID=47780096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100034T CY1121296T1 (el) | 2011-12-15 | 2019-01-14 | Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9550821B2 (enExample) |
| EP (1) | EP2790721B8 (enExample) |
| JP (1) | JP6031121B2 (enExample) |
| CA (1) | CA2857276A1 (enExample) |
| CY (1) | CY1121296T1 (enExample) |
| DK (1) | DK2790721T3 (enExample) |
| ES (1) | ES2705499T3 (enExample) |
| HR (1) | HRP20190062T1 (enExample) |
| HU (1) | HUE042102T2 (enExample) |
| LT (1) | LT2790721T (enExample) |
| PL (1) | PL2790721T3 (enExample) |
| PT (1) | PT2790721T (enExample) |
| RS (1) | RS58237B1 (enExample) |
| SI (1) | SI2790721T1 (enExample) |
| TR (1) | TR201900438T4 (enExample) |
| WO (1) | WO2013088241A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042102T2 (hu) | 2011-12-15 | 2019-06-28 | Millendo Therapeutics Sas | Acilezetlen grelin fragmensek Prader-Willi szindróma kezelésében történõ alkalmazásra |
| US20160151458A1 (en) | 2013-06-21 | 2016-06-02 | Alize Pharma Sas | Use Of Unacylated Ghrelin, Fragments And Analogs Thereof As Antioxidant |
| EP3193939A4 (en) * | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| KR102323613B1 (ko) | 2014-11-14 | 2021-11-09 | 에센셜리스 인코포레이티드 | 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법 |
| US10053693B2 (en) | 2016-01-19 | 2018-08-21 | Mubin I. Syed | Method for controlling obesity using minimally invasive means |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| US6627729B1 (en) | 1997-03-24 | 2003-09-30 | Zymogenetics, Inc. | TML peptides |
| AU6515499A (en) | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
| WO2001056592A1 (en) | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
| AU2001259056A1 (en) | 2000-05-17 | 2001-11-26 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| JP2004514651A (ja) | 2000-05-30 | 2004-05-20 | メルク エンド カムパニー インコーポレーテッド | グレリン類似体 |
| US6872548B2 (en) | 2001-01-31 | 2005-03-29 | Human Genome Sciences, Inc. | Scaffolded fusion polypeptides and compositions and methods for making the same |
| JP4493913B2 (ja) | 2001-01-31 | 2010-06-30 | 中外製薬株式会社 | 低栄養症状疾患治療剤 |
| JP4562394B2 (ja) | 2001-12-18 | 2010-10-13 | アリゼ、ファルマ、エスアーエス | 非アシル化グレリンを含む医薬組成物およびその治療的使用 |
| CA2470235C (en) | 2001-12-18 | 2012-02-07 | Theratechnologies Inc. | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| JP5000848B2 (ja) | 2002-05-21 | 2012-08-15 | 第一三共株式会社 | グレリン含有医薬組成物 |
| US7825090B2 (en) | 2003-10-24 | 2010-11-02 | Alizé Pharma SAS | Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance |
| EP1812044A2 (en) | 2004-10-27 | 2007-08-01 | Gastrotech Pharma A/S | Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure |
| US8653022B2 (en) | 2006-03-28 | 2014-02-18 | Liat Mintz | Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia |
| US8318664B2 (en) * | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
| WO2008145749A1 (en) | 2007-05-31 | 2008-12-04 | Alize Pharma Sas | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
| EP2067481A1 (en) | 2007-12-03 | 2009-06-10 | Charité-Universitätsmedizin Berlin | Therapeutic use of desacyl ghrelin |
| US8476408B2 (en) * | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| HUE042102T2 (hu) | 2011-12-15 | 2019-06-28 | Millendo Therapeutics Sas | Acilezetlen grelin fragmensek Prader-Willi szindróma kezelésében történõ alkalmazásra |
-
2012
- 2012-12-14 HU HUE12829142A patent/HUE042102T2/hu unknown
- 2012-12-14 US US13/715,550 patent/US9550821B2/en not_active Expired - Fee Related
- 2012-12-14 EP EP12829142.4A patent/EP2790721B8/en active Active
- 2012-12-14 PL PL12829142T patent/PL2790721T3/pl unknown
- 2012-12-14 PT PT12829142T patent/PT2790721T/pt unknown
- 2012-12-14 TR TR2019/00438T patent/TR201900438T4/tr unknown
- 2012-12-14 JP JP2014546665A patent/JP6031121B2/ja not_active Expired - Fee Related
- 2012-12-14 RS RS20190033A patent/RS58237B1/sr unknown
- 2012-12-14 LT LTEP12829142.4T patent/LT2790721T/lt unknown
- 2012-12-14 ES ES12829142T patent/ES2705499T3/es active Active
- 2012-12-14 DK DK12829142.4T patent/DK2790721T3/en active
- 2012-12-14 US US14/364,228 patent/US20140336109A1/en not_active Abandoned
- 2012-12-14 SI SI201231504T patent/SI2790721T1/sl unknown
- 2012-12-14 CA CA2857276A patent/CA2857276A1/en not_active Abandoned
- 2012-12-14 HR HRP20190062TT patent/HRP20190062T1/hr unknown
- 2012-12-14 WO PCT/IB2012/002867 patent/WO2013088241A1/en not_active Ceased
-
2019
- 2019-01-14 CY CY20191100034T patent/CY1121296T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2790721T3 (en) | 2019-02-04 |
| JP6031121B2 (ja) | 2016-11-24 |
| JP2015501832A (ja) | 2015-01-19 |
| PT2790721T (pt) | 2019-01-24 |
| ES2705499T3 (es) | 2019-03-25 |
| EP2790721B1 (en) | 2018-10-17 |
| PL2790721T3 (pl) | 2019-05-31 |
| EP2790721A1 (en) | 2014-10-22 |
| US20140336109A1 (en) | 2014-11-13 |
| LT2790721T (lt) | 2019-02-11 |
| US9550821B2 (en) | 2017-01-24 |
| HRP20190062T1 (hr) | 2019-03-08 |
| HUE042102T2 (hu) | 2019-06-28 |
| EP2790721B8 (en) | 2018-11-28 |
| SI2790721T1 (sl) | 2019-03-29 |
| RS58237B1 (sr) | 2019-03-29 |
| CA2857276A1 (en) | 2013-06-20 |
| TR201900438T4 (tr) | 2019-02-21 |
| US20130157936A1 (en) | 2013-06-20 |
| WO2013088241A1 (en) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121296T1 (el) | Θραυσματα μη ακυλιωμενης γκρελινης για χρηση στη θεραπεια συνδρομου prader-willi | |
| EA201490559A1 (ru) | Композиция для лечения свища | |
| EA201491303A1 (ru) | Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps | |
| EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
| EA201101053A1 (ru) | Ингибиторы фосфоиноз итид-3-киназ с цинксвязывающей группой | |
| CY1123716T1 (el) | Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| MX385616B (es) | Inhibidores de cdk | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| EA201490268A1 (ru) | Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор | |
| EA032501B9 (ru) | Способы и композиции для содействия заживлению острой раны и хронической раны | |
| MX2015014329A (es) | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. | |
| UY33833A (es) | Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma | |
| EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
| CY1119413T1 (el) | Μεθοδος για την παραγωγη και τη χρηση ενος συμπολυμερους νατριουχου καρβοξυμεθυλοκυτταρινης και γκοσυπολης | |
| BR112015002531A2 (pt) | composição, método de tratamento de hipersensibilidade e uso de carbonato de cálcio. | |
| PH12014502109A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| WO2013074816A3 (en) | Novel inhibitors of nox1 | |
| EA201390757A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА | |
| EA201301080A1 (ru) | Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания | |
| AR081772A1 (es) | Tratamiento de la artritis reumatoide con masitinib | |
| EA201492173A1 (ru) | Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе | |
| MX2012012509A (es) | Tapentadol para usarse en el tratamiento del sindrome del intestino irritable. | |
| Symochko | Monitoring of Soil Microbial Coenosis in Primeval Beech Forests | |
| UA57313U (ru) | Способ определения твердости асфальтобетонных покрытий |